Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 14/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17582259 | 0.84 | SCN9A (0.56) | SCN9ASCN10ASCN5A | |
| SCHEMBL305521 | 0.83 | SCN9A (0.48) | SCN9ACYP17A1CYP1A2SCN10A | |
| SCHEMBL304556 | 0.81 | CYP17A1 (0.45) | SCN9ACYP17A1CYP1A2HDAC9 | |
| SCHEMBL441028 | 0.79 | CYP1A2 (0.54) | CYP17A1CYP1A2 | |
| SCHEMBL25342346 | 0.76 | CYP17A1 (0.60) | SCN9ACYP17A1CYP1A2 | |
| SCHEMBL17582150 | 0.74 | SCN9A (0.83) | SCN9ASCN10ASCN5A | |
| SCHEMBL15491624 | 0.72 | CYP17A1 (0.46) | SCN9ACYP17A1CYP1A2 | |
| SCHEMBL30568648 | 0.71 | CYP17A1 (0.44) | SCN9ACYP17A1CYP1A2 | |
| SCHEMBL25343903 | 0.70 | MAPK14 (0.49) | SCN9ACYP17A1CYP1A2 | |
| SCHEMBL25343352 | 0.70 | MAPK14 (0.49) | SCN9ACYP17A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4472739-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023148129-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-10 | — | — | WO | disclosed |